A phase 3 trial of Shionogi’s baloxavir marboxil (Xofluza) has found that a single dose of the antiviral flu drug was superior to placebo and similar to oseltamivir (Tamiflu) in shortening the duration of illness in adult and adolescent outpatients at high risk for flu-related complications. The study, published yesterday in The Lancet Infectious Diseases, also showed that baloxavir stopped viral shedding sooner and caused fewer adverse events, such as sinusitis, bronchitis, and nausea, than placebo, mostly in those receiving treatment within 36 hours of symptom onset.

 

Credit: Pixabay

Read more CIDRAP…